Literature DB >> 30766403

Positivity Rates in Oropharyngeal and Nonoropharyngeal Head and Neck Cancer in the VA.

John Park1, Veronica McPike1, Suman Kambhampati1, Chao Huang1, January Fields-Meehan1, Linda Verkruyse1, Ace Allen1, Eashwer Reddy1.   

Abstract

The rates of human papillomavirus positivity of the p16 biomarker in veterans were similar to those of patients with oropharyngeal head and neck tumors in the general population, but differed from general population patients with nonoropharyngeal squamous cell carcinoma.

Entities:  

Year:  2018        PMID： 30766403      PMCID： PMC6248148     

Source DB:  PubMed          Journal:  Fed Pract        ISSN： 1078-4497


  4 in total

1.  Risk factors for human papillomavirus-positive nonoropharyngeal squamous cell carcinoma.

Authors:  Melina J Windon; Gypsyamber D'Souza; Tim Waterboer; Lisa Rooper; William H Westra; Tanya Troy; Drew Pardoll; Marietta Tan; Siddhartha Yavvari; Ana P Kiess; Brett Miles; Wojciech K Mydlarz; Patrick K Ha; Noemi Bender; David W Eisele; Carole Fakhry
Journal:  Head Neck       Date:  2020-02-26       Impact factor: 3.147

2.  CD8 infiltration is associated with disease control and tobacco exposure in intermediate-risk oropharyngeal cancer.

Authors:  J O Kemnade; H Elhalawani; P Castro; J Yu; S Lai; M Ittmann; A S R Mohamed; S Y Lai; C D Fuller; A G Sikora; V C Sandulache
Journal:  Sci Rep       Date:  2020-01-14       Impact factor: 4.379

Review 3.  A Hidden Epidemic of "Intermediate Risk" Oropharynx Cancer.

Authors:  Vlad C Sandulache; David C Wilde; Erich M Sturgis; Elizabeth Y Chiao; Andrew G Sikora
Journal:  Laryngoscope Investig Otolaryngol       Date:  2019-10-17

4.  Incidence and survival for oropharynx and non-oropharynx head and neck cancers among veterans living with HIV.

Authors:  Angela L Mazul; Christine Hartman; Jennifer Kramer; Donna L White; Kathryn Royse; Suchismita Raychaudhury; Vlad Sandulache; Sarah T Ahmed; Peter Richardson; Andrew G Sikora; Elizabeth Chiao
Journal:  Cancer Med       Date:  2020-10-23       Impact factor: 4.452
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.